Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M77,811Revenue $M19,616Net Margin (%)12.2Z-Score3.7
Enterprise Value $M81,055EPS $2.2Operating Margin %17.0F-Score4
P/E(ttm))31.5Cash Flow Per Share $5.4Pre-tax Margin (%)15.3Higher ROA y-yN
Price/Book5.110-y EBITDA Growth Rate %14.8Quick Ratio0.8Cash flow > EarningsY
Price/Sales3.85-y EBITDA Growth Rate %-9.4Current Ratio1.1Lower Leverage y-yN
Price/Cash Flow9.1y-y EBITDA Growth Rate %-39.0ROA % (ttm)6.8Higher Current Ratio y-yN
Dividend Yield %2.8Insider Buy (3m)0ROE % (ttm)13.7Less Shares Outstanding y-yY
Payout Ratio %88.0Shares Outstanding M1,111ROI % (ttm)23.7Gross Margin Increase y-yN

Gurus Latest Trades with LLY

Number of guru portfolios checked: 85. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
LLYKen Fisher 2014-12-31 Add0.07%$61.9 - $72.83
($67.53)
$ 70.364%Add 383.26%578,992
LLYRay Dalio 2014-12-31 Buy $61.9 - $72.83
($67.53)
$ 70.364%New holding, 4639 sh.4,639
LLYCharles Brandes 2014-12-31 Reduce-1.85%$61.9 - $72.83
($67.53)
$ 70.364%Reduce -92.65%169,348
LLYJohn Hussman 2014-12-31 Reduce-0.29%$61.9 - $72.83
($67.53)
$ 70.364%Reduce -17.21%252,500
LLYRichard Pzena 2014-12-31 Sold Out -0.15%$61.9 - $72.83
($67.53)
$ 70.364%Sold Out0
LLYJohn Hussman 2014-09-30 Add1.67%$60.35 - $66.59
($63.3)
$ 70.3611%Add 6000%305,000
LLYKen Fisher 2014-09-30 Add0.02%$60.35 - $66.59
($63.3)
$ 70.3611%Add 2742.47%119,810
LLYDodge & Cox 2014-09-30 Add$60.35 - $66.59
($63.3)
$ 70.3611%Add 20.38%42,464
LLYJoel Greenblatt 2014-09-30 Reduce$60.35 - $66.59
($63.3)
$ 70.3611%Reduce -27.37%5,628
LLYCharles Brandes 2014-09-30 Reduce-0.29%$60.35 - $66.59
($63.3)
$ 70.3611%Reduce -14.27%2,303,062
LLYHOTCHKIS & WILEY 2014-09-30 Reduce-0.12%$60.35 - $66.59
($63.3)
$ 70.3611%Reduce -10.92%4,321,666
LLYDavid Dreman 2014-09-30 Reduce-0.02%$60.35 - $66.59
($63.3)
$ 70.3611%Reduce -84.4%900
LLYGeorge Soros 2014-09-30 Sold Out -0.02%$60.35 - $66.59
($63.3)
$ 70.3611%Sold Out0
LLYHOTCHKIS & WILEY 2014-06-30 Add0.73%$58.21 - $63.1
($59.62)
$ 70.3618%Add 199.7%4,851,480
LLYGeorge Soros 2014-06-30 Buy 0.02%$58.21 - $63.1
($59.62)
$ 70.3618%New holding, 50441 sh.50,441
LLYVanguard Health Care Fund 2014-06-30 Reduce-0.15%$58.21 - $63.1
($59.62)
$ 70.3618%Reduce -3.98%21,982,700
LLYJohn Hussman 2014-06-30 Reduce-0.02%$58.21 - $63.1
($59.62)
$ 70.3618%Reduce -50%5,000
LLYRay Dalio 2014-06-30 Sold Out -0.02%$58.21 - $63.1
($59.62)
$ 70.3618%Sold Out0
LLYPRIMECAP Management 2014-03-31 Add0.37%$50.73 - $59.85
($55.61)
$ 70.3626%Add 10.83%57,129,708
LLYHOTCHKIS & WILEY 2014-03-31 Buy 0.35%$50.73 - $59.85
($55.61)
$ 70.3626%New holding, 1618802 sh.1,618,802
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

LLY is held by these Gurus:

Ticker Guru Name Portfolio Date* Current Shares % of Shares Outstanding % of Total Assets Managed Change from Last Holdings Holding History
LLY Ray Dalio 2014-12-314,63900New Buy
LLY Ken Fisher 2014-12-31578,9920.050.08+383.26%
LLY PRIMECAP Management 2014-12-3157,592,7015.184+0.86%
LLY Joel Greenblatt 2014-12-315,63400+0.11%
LLY David Dreman 2014-12-3190000.01
LLY Vanguard Health Care Fund 2014-12-3121,982,7001.983.6
LLY Mario Gabelli 2014-12-31113,8000.010.04-0.7%
LLY Dodge & Cox 2014-12-3139,00400-8.15%
LLY HOTCHKIS & WILEY 2014-12-313,940,5870.350.95-8.82%
LLY John Hussman 2014-12-31252,5000.021.7-17.21%
LLY Charles Brandes 2014-12-31169,3480.020.16-92.65%
LLY Richard Pzena 2014-12-31000Sold Out
Premium Most recent portfolio changes are included for Premium Members only!


LLY: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Zakrowski Donald AChief Accounting Officer 2015-02-05Sell374$71.03-1.76view
Rice Derica WEVP-Global Services and CFO 2015-02-04Sell5,316$70-0.31view
Lundberg Jan MEVP,Science&Tech and Pres. LRL 2015-02-04Sell11,085$70.08-0.43view
Ricks David ASVP and Pres, Lilly Bio-Meds 2015-02-04Sell3,147$69.99-0.3view
Lundberg Jan MEVP,Science&Tech and Pres. LRL 2015-02-03Sell121,711$70.78-1.41view
Ricks David ASVP and Pres, Lilly Bio-Meds 2015-02-02Sell4,769$71.51-2.42view
Rice Derica WEVP-Global Services and CFO 2015-02-02Sell10,068$71.84-2.87view
LILLY ENDOWMENT INC10% Owner 2014-12-04Sell190,000$71.92-2.98view
LILLY ENDOWMENT INC10% Owner 2014-12-02Sell180,000$70.14-0.51view
LILLY ENDOWMENT INC10% Owner 2014-11-13Sell200,000$67.733.03view

Press Releases about LLY :

    Quarterly/Annual Reports about LLY:

    News about LLY:

    Articles On GuruFocus.com
    Feeling Good With This Med Company Jan 20 2015 
    Sarah Ketterer Dives in when Others Pull Out Nov 14 2014 
    Weekly 52-Week Highs Highlight: LLY, BG, NVS, HRL Sep 07 2014 
    Higher Yielding Stocks With A Cheap EV/EBITDA Ratio And Low Debt Figures Aug 28 2014 
    Eli Lilly is on the Right Track Jun 25 2014 
    John Paulson's Stocks Trading for Less Than He Paid for Them Jun 02 2014 
    Johnson & Johnson (JNJ) Dividend Stock Analysis May 29 2014 
    Can Pfizer Make Up Its Loss? May 09 2014 
    Will Pfizer’s Q1 2014 Earnings Beat the Street on May 5, 2014? May 05 2014 
    Vanguard Health Care Fund's Top Quarterly Holdings Apr 30 2014 


    More From Other Websites
    MannKind Reports Narrower Y/Y Loss in Q4, Afrezza in Focus - Analyst Blog Feb 25 2015
    Lilly to Present at Cowen Health Care Conference Feb 24 2015
    Bristol-Myers to Buy Flexus, Team Up with Rigel - Analyst Blog Feb 24 2015
    Huge response to high-quality trades on busy issuance day Feb 24 2015
    Eli Lilly's BIL Filing Delayed, Baricitinib Scores in Phase III - Analyst Blog Feb 24 2015
    Lilly to Present at Cowen Health Care Conference Feb 24 2015
    Eli Lilly stays out of deals fray as it eyes 'moon shot' drugs Feb 24 2015
    Lilly long-acting insulin delayed by liver concerns Feb 23 2015
    Lilly Delays Diabetes Treatment Submission Feb 23 2015
    Lilly delays submission to market once-daily diabetes drug Feb 23 2015
    Lilly Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro Feb 23 2015
    Lilly Announces Update on Regulatory Submission Timing for Basal Insulin Peglispro Feb 23 2015
    Baricitinib Superior to Placebo in Reducing Rheumatoid Arthritis Disease Activity in Second Phase 3... Feb 23 2015
    High Value But Little Glory: Innovating The Unmentionable Feb 22 2015
    NASCAR Driver Ryan Reed Takes First Place At Daytona International Speedway Feb 21 2015
    10-K for Eli Lilly & Co. Feb 21 2015
    Eli Lilly Extends Phase III Cholesterol Study by Six Months - Analyst Blog Feb 20 2015
    LILLY ELI & CO Files SEC form 10-K, Annual Report Feb 19 2015
    Lilly Extends Cholesterol Therapy Study Feb 19 2015
    Lilly Provides Update on Evacetrapib Phase 3 Trial Feb 19 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK